Intrathecal injection of CD133-positive enriched bone marrow progenitor cells in children with cerebral palsy: feasibility and safety

Zali, Alireza; Arab, Leila; Ashrafi, Farzad; Mardpour, Soura; Niknejhadi, Maryam; Hedayatiasl, A. A.; Halimi-Asl, Aliasghar; Ommi, Davood; Hosseini, Seyyedeh-Esmat; Baharvand, Hossein; Aghdami, Nasser

doi:10.1016/j.jcyt.2014.10.011

Cited by 29 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, to achieve a valid pooled motor function change following stem cell therapy in CP patients, further trials with the same protocols should be performed. However, the present clinical trials and case reports could demonstrate beneficial effects of stem cell therapy on motor function in patients with CP (15)(16)(17)(18)(19)(20).…”

Section: Discussionmentioning

confidence: 62%

“…On the other hand, stem cell therapy with the different protocols, including autologous MSC therapy or human embryonic stem cell therapy, could result in an increase of motor function in patients with CP. However, considering these assessed trials, indicated a significant heterogeneity between the studies (15)(16)(17)(18)(19). In fact, because of the difference in treatment protocols as well as different gap periods between treatment phases, the change in motor function was found to be widely varied between the studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement

et al. 2018

Self Cite

View full text Add to dashboard Cite

The current knowledge on how to use stem cells therapeutically for improving motor function in patients with cerebral palsy is growing. The present review aimed at assessing clinical trials related to beneficial effects of stem cells in patients with cerebral palsy. Electronic searches including "stem cell" and "cerebral palsy" as keywords were conducted using PubMed, Ovid, Web of Science, Scopus, Cochrane library, and CINAHL till February 2016. Two assessors reviewed the methodological quality and eligibility of the retrieved articles, independently. Among 77 studies initially reviewed based on the keywords, only 6 clinical trials were identified that met the inclusion criteria. Pooled response rate of stem cell therapy to treat cerebral palsy was estimated by assessing the percentage of improvement with a gross motor function classification system score. The resulting pooled estimate indicated a 30.7% (95% CI: 25.80% to 35.69%) increase in the score, 1 to 6 months after cell transplantation. In this regard, the test for heterogeneity was statistically significant (I2 = 87.9%, χ 2 = 41.22, P < 0.0001). Stem cell therapy has the potential to improve motor function in patients with cerebral palsy. However, promising results from limited studies warrant further research.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…The phenotype of CD34 + HSCs indicates the concurrent absence of CD38 and the expression of CD133 [56]. Bone marrow-derived hematopoietic stem cells (HSCs) are classified as CD133 + cells, upholding a strong potential for angiogenesis, neuroprotective and neurotrophic factor secretion, a robust capability for proliferation and less immunogenicity potency [57]. Once purified and freed from leukocytes and their progenitors, HSCs can significantly decrease high inflammatory reactions at graft sites [57].…”

Section: Hematopoietic Stem Cellsmentioning

confidence: 99%

“…Bone marrow-derived hematopoietic stem cells (HSCs) are classified as CD133 + cells, upholding a strong potential for angiogenesis, neuroprotective and neurotrophic factor secretion, a robust capability for proliferation and less immunogenicity potency [57]. Once purified and freed from leukocytes and their progenitors, HSCs can significantly decrease high inflammatory reactions at graft sites [57]. Twelve CP patients from both genders and aged between 4 and 12 years underwent bone marrow aspiration, where approximately 60 mL of bone marrow was aspirated from the patient's iliac crest [57].…”

Section: Hematopoietic Stem Cellsmentioning

confidence: 99%

“…Once purified and freed from leukocytes and their progenitors, HSCs can significantly decrease high inflammatory reactions at graft sites [57]. Twelve CP patients from both genders and aged between 4 and 12 years underwent bone marrow aspiration, where approximately 60 mL of bone marrow was aspirated from the patient's iliac crest [57]. Flow cytometry-based quality control measurements were performed in order to determine the amount of CD133 + cells in the unselected bone marrow cell preparations and in the CD133-enriched preparations [57].…”

Section: Hematopoietic Stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Untitled

2020

JSCR

View full text Add to dashboard Cite

As the gestational age at birth decreases, the risk of the infant having CP increases [6]. Detections of CP among premature births are mostly found through white matter damage on brain-imaging modalities [6]. Evidence of single or multiple brain lesions or ventriculomegaly in a pre-term infant leads to a 50% risk of developing CP [6]. The prenatal Abstract Cerebral palsy (CP) is a neurodevelopmental disorder that hinders normal motor activity and muscle coordination. CP typically appears before, during, or soon after birth as the brain is still developing. The severity of this multifactorial condition depends on the damage done to the parts of the brain that control muscle tone and body movement. The insult in the underdeveloped brain prohibits normal growth; neurons and oligodendrocytes will either die or fail to develop, and the white matter tracts that connect various brain regions become malfunctional. Cerebral palsy is classified into different types depending on the areas of the brain that were insulted and the nature of the movement disorder: spasticity, dyskinesia, and ataxia. Abnormal brain development in patients with CP cannot be reversed, but various treatments are shown to improve and normalize the symptoms. Stem cell transplantation, a regenerative therapy that can replace the damaged and non-functional cells of the brains in CP patients, has shown effective results. Embryonic stem cells (ESC), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), human amnion epithelial cells (hAEC), and neural stem cells (NSC) are infused to reproduce into more specialized cell types. This alternative therapeutic method has shown successful results through preclinical animal research and clinical trials.

show abstract

A systematic review of cell therapy modalities and outcomes in cerebral palsy

Akat,

Karaöz

2024

Mol Cell Biochem

View full text Add to dashboard Cite

Intrathecal injection of CD133-positive enriched bone marrow progenitor cells in children with cerebral palsy: feasibility and safety

Cited by 29 publications

References 34 publications

A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement

A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement

Untitled

A systematic review of cell therapy modalities and outcomes in cerebral palsy

Contact Info

Product

Resources

About